Our
News
Check back on a regualr basis
for futher updates.
VasoDynamics Receives UK-Taiwan Collaborative R&D Grant
VasoDynamics Receives UK-Taiwan Collaborative R&D Grant VasoDynamics receives Grant to Progress Organ-on-Chip Technology with Partner Genenet 25th November 2024 - VasoDynamics Ltd, the pharmaceutical company developing
VasoDynamics Undertakes Pivotal Trial Scientific Advisory Meeting with Regulatory Authority in the Netherlands to Discuss Next Steps in NG11-2 Development Programme
VasoDynamics Undertakes Pivotal Trial Scientific Advisory Meeting with Regulatory Authority in the Netherlands to Discuss Next Steps in NG11-2 Development Programme 18th October 2024 - VasoDynamics
VasoDynamics strengthens financial management with key appointment to enable progress to market access
VasoDynamics strengthens financial management with key appointment to enable progress to market access 3rd September 2024 - VasoDynamics Ltd, the pharmaceutical company developing preventive therapies for
VasoDynamics strengthens the Board with key appointments
VasoDynamics strengthens the Board with key appointments Building a strong Board of industry experts to enable progress to market acces • Dr Laurence Reilly, Non-executive Chair
NG11-2 Phase-Ib Study Completes Last Patient Visit
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
NG11-2 Phase-Ib Study Closes Enrolment – Results Expected Autumn 2024
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer.
